PD-L1 is highly expressed in tumor cells and antigen-presenting cells within the tumor microenvironment, making PD-L1 immune checkpoint inhibitors (ICIs) crucial for cancer treatment (Liu et al., 2017). Here, CD274 is linked to neoplasm.